TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 32158971

Group type: EXPERIMENTAL
Intervention: Continuous antibiotic prophylaxis (CAP) until hydronephrosis resolution or aged 12 months (n=40)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Watchful observation (control group, n=40)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Continuous antibiotic prophylaxis (CAP)
Number of subjects: 80
Study: 35512620

Group type: EXPERIMENTAL
Intervention: Virtual reality-based computer AT system (CATS)
Number of subjects: 65

Group type: COMPARATOR
Intervention: Cognitive-behavioral therapy (CBT)
Number of subjects: 65

Group type: EXPERIMENTAL
Intervention: Visual P300 component
Number of subjects: 65
Study: 33962686

Group type: EXPERIMENTAL
Intervention: Educational intervention based on the Social Marketing Model
Number of subjects: 94
Study: 32802833

Group type: EXPERIMENTAL
Intervention: Botulinum toxin type A (BTA)
Number of subjects: 63

Group type: EXPERIMENTAL
Intervention: Botulinum toxin type A (BTA) combined with oral finasteride (FNS)
Number of subjects: 63
Study: 32607820

Group type: EXPERIMENTAL
Intervention: Intelligent 'Internet Plus'-based full disease cycle remote ischemic conditioning (i-RIC)
Number of subjects: 4700

Group type: COMPARATOR
Intervention: Control group receiving PCI and usual care
Number of subjects: 4700
Study: 32059663

Group type: EXPERIMENTAL
Intervention: Locally tailored preconception care (PCC) approach
Number of subjects: 2000
Study: 35293588

Group type: EXPERIMENTAL
Intervention: Unilateral task-oriented training with dynamic hand orthosis (30 min per day)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Unilateral task-oriented training without dynamic hand orthosis
Number of subjects: 30
Study: 32860964

Group type: EXPERIMENTAL
Intervention: Tocilizumab
Number of subjects: 778

Group type: EXPERIMENTAL
Intervention: Intermediate-high dose corticosteroids (IHDC)
Number of subjects: 778

Group type: EXPERIMENTAL
Intervention: Pulse dose corticosteroids (PDC)
Number of subjects: 778

Group type: EXPERIMENTAL
Intervention: Combination therapy
Number of subjects: 778

Group type: COMPARATOR
Intervention: No treatment (Control)
Number of subjects: 778

Group type: EXPERIMENTAL
Intervention: PDC
Number of subjects: 778
Study: 34817191

Group type: EXPERIMENTAL
Intervention: Gadobenate-enhanced MRI (0.05 mmol/kg)
Number of subjects: 126

Group type: COMPARATOR
Intervention: Gadoxetate-enhanced MRI (0.025 mmol/kg)
Number of subjects: 126

Group type: EXPERIMENTAL
Intervention: Both gadobenate and gadoxetate
Number of subjects: 126
Study: 33577800

Group type: EXPERIMENTAL
Intervention: Rivaroxaban 10 mg once daily for 35 days
Number of subjects: 4000

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 4000
Study: 35987309

Group type: EXPERIMENTAL
Intervention: Advanced hybrid closed loop (AHCL) system with adjusted settings
Number of subjects: 42

Group type: COMPARATOR
Intervention: Control group with unchanged AHCL settings
Number of subjects: 42
Study: 34253219

Group type: EXPERIMENTAL
Intervention: Postoperative spinal orthosis (Group A)
Number of subjects: 90

Group type: COMPARATOR
Intervention: No postoperative spinal orthosis (Group B)
Number of subjects: 90
Study: 34429030

Group type: EXPERIMENTAL
Intervention: High-Intensity Interval Training (HIIT)
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: Self-Selected Intensity Training (SSIT)
Number of subjects: 64

Group type: COMPARATOR
Intervention: Moderate-Intensity Continuous Training (MICT)
Number of subjects: 64
Study: 33906786

Group type: EXPERIMENTAL
Intervention: Medial unicompartmental knee arthroplasty (UKA) in LM (+) group
Number of subjects: 125

Group type: COMPARATOR
Intervention: Medial unicompartmental knee arthroplasty (UKA) in LM (−) group
Number of subjects: 125

Group type: EXPERIMENTAL
Intervention: Radiological evaluation of implant position and mechanical axis in LM (+) group
Number of subjects: 125

Group type: COMPARATOR
Intervention: Radiological evaluation of implant position and mechanical axis in LM (−) group
Number of subjects: 125
Study: 32575605

Group type: EXPERIMENTAL
Intervention: Noodles made from yellow pea
Number of subjects: 12
Study: 36335191

Group type: EXPERIMENTAL
Intervention: Domagrozumab
Number of subjects: 120

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 120
Study: 32144319

Group type: EXPERIMENTAL
Intervention: Lab4P probiotic (50 billion/day)
Number of subjects: 220
Study: 34609303

Group type: COMPARATOR
Intervention: Proton-pump-based triple therapy (PpTT) for 2 weeks
Number of subjects: 400

Group type: COMPARATOR
Intervention: Sequential therapy for 2 weeks
Number of subjects: 400

Group type: EXPERIMENTAL
Intervention: Proton-pump-based triple therapy plus bovine lactoferrin for 2 weeks
Number of subjects: 400

Group type: EXPERIMENTAL
Intervention: Sequential therapy plus bovine lactoferrin for 2 weeks
Number of subjects: 400
Study: 33203627

Group type: EXPERIMENTAL
Intervention: Methotrexate (MTX) plus 20 weeks of prednisolone
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo plus 20 weeks of prednisolone
Number of subjects: 0
Study: 36175293

Group type: EXPERIMENTAL
Intervention: Romifidine IV (80 μg kg–1 premedication, 40 μg kg–1 hour–1 maintenance, 20 μg kg–1 before recovery)
Number of subjects: 63

Group type: EXPERIMENTAL
Intervention: Detomidine IV (15 μg kg–1 premedication, 5 μg kg–1 hour–1 maintenance, 2.5 μg kg–1 before recovery)
Number of subjects: 63

Group type: EXPERIMENTAL
Intervention: Detomidine IV (15 μg kg–1 premedication, 5 μg kg–1 hour–1 maintenance, 5 μg kg–1 before recovery)
Number of subjects: 63
Study: 34319275

Group type: EXPERIMENTAL
Intervention: Enteric-coated peppermint oil 180 mg 3 times daily
Number of subjects: 180

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 180
Study: 35943064

Group type: EXPERIMENTAL
Intervention: Therapist-assisted Internet-delivered cognitive therapy for SAD (OSCA)
Number of subjects: 43

Group type: COMPARATOR
Intervention: Waitlist control
Number of subjects: 43
Study: 33857455

Group type: EXPERIMENTAL
Intervention: Staggered group (single desynchronised monthly payments)
Number of subjects: 194

Group type: EXPERIMENTAL
Intervention: Split and staggered group (desynchronised payments split into two instalments per month)
Number of subjects: 194

Group type: COMPARATOR
Intervention: Control group (monthly synchronised payments)
Number of subjects: 194
Study: 32114475

Group type: EXPERIMENTAL
Intervention: Extreme hypofractionated radiotherapy with stereotactic body radiation therapy to 36.25 Gy/5# (7 to 10 days)
Number of subjects: 434

Group type: COMPARATOR
Intervention: Moderate hypofractionation schedule of 68 Gy/25# over 5 weeks
Number of subjects: 434

Group type: EXPERIMENTAL
Intervention: Overall survival, prostate cancer specific survival, acute and late toxicities, quality of life, and out-of-pocket expenditure
Number of subjects: 434
Study: 33068641

Group type: EXPERIMENTAL
Intervention: Adrenaline, oxygen, patient positioning, glucagon
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Adrenaline dosing and frequency
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Antihistamines and corticosteroids
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Recommendations based on low-level evidence
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: New evidence in the last decade
Number of subjects: 0
Study: 34238042

Group type: EXPERIMENTAL
Intervention: HF with assertive community treatment (HF-ACT)
Number of subjects: 527

Group type: EXPERIMENTAL
Intervention: HF with intensive case management (HF-ICM)
Number of subjects: 527

Group type: COMPARATOR
Intervention: Treatment as usual (TAU)
Number of subjects: 527
Study: 33157939

Group type: EXPERIMENTAL
Intervention: Clostridium butyricum (C butyricum)
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Bacillus coagulans (B coagulans)
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Clostridium butyricum plus Bacillus coagulans (C butyricum + B coagulans)
Number of subjects: 150

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 150
Study: 36173415

Group type: EXPERIMENTAL
Intervention: Romosozumab 210 mg monthly for 12 months
Number of subjects: 3013

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 3013
Study: 33395175

Group type: EXPERIMENTAL
Intervention: Silver-impregnated fibrous hydrocolloid (SFH) dressings
Number of subjects: 70

Group type: COMPARATOR
Intervention: Topical silver sulfadiazine (SS) cream
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 70
Study: 33529449

Group type: EXPERIMENTAL
Intervention: TAU + IRT
Number of subjects: 219

Group type: EXPERIMENTAL
Intervention: TAU + mianserin
Number of subjects: 219

Group type: EXPERIMENTAL
Intervention: TAU + IRT + mianserin
Number of subjects: 219

Group type: COMPARATOR
Intervention: TAU
Number of subjects: 219
Study: 32641367

Group type: EXPERIMENTAL
Intervention: Connectivity guided intermittent theta burst stimulation (cgiTBS)
Number of subjects: 368

Group type: COMPARATOR
Intervention: Neuronavigated repetitive transcranial magnetic stimulation (rTMS)
Number of subjects: 368

Group type: EXPERIMENTAL
Intervention: Self-rated depression, anxiety, psychosocial functioning, cognition and quality of life assessments
Number of subjects: 368

Group type: EXPERIMENTAL
Intervention: Cost-effectiveness, patient acceptability, safety, mechanism of action and predictors of response
Number of subjects: 368
Study: 35529453

Group type: EXPERIMENTAL
Intervention: Short-term spinal cord stimulation (stSCS)
Number of subjects: 70

Group type: COMPARATOR
Intervention: Pulsed radiofrequency (PRF)
Number of subjects: 70
Study: 32814589

Group type: EXPERIMENTAL
Intervention: Horizontal sperm migration in injection dishes (Group B)
Number of subjects: 1034

Group type: COMPARATOR
Intervention: Conventional swim-up method (Group A)
Number of subjects: 1034
Study: 35980316

Group type: EXPERIMENTAL
Intervention: Novel dental gel containing 0.454% stannous fluoride and 2.6% EDTA
Number of subjects: 60

Group type: COMPARATOR
Intervention: Dentifrice with 0.24% sodium fluoride
Number of subjects: 60
Study: 33589269

Group type: EXPERIMENTAL
Intervention: H2SO4-etched PEEK with universal adhesive conditioning for 0 min
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: H2SO4-etched PEEK with universal adhesive conditioning for 1 min
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: H2SO4-etched PEEK with universal adhesive conditioning for 3 min
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: H2SO4-etched PEEK with universal adhesive conditioning for 5 min
Number of subjects: 70

Group type: COMPARATOR
Intervention: Untreated PEEK with acidic adhesive conditioning (all time points)
Number of subjects: 70
Study: 35441210

Group type: EXPERIMENTAL
Intervention: 1000 IU/d vitamin D
Number of subjects: 118

Group type: COMPARATOR
Intervention: 400 IU/d vitamin D
Number of subjects: 118

Group type: COMPARATOR
Intervention: Reference group (400 IU/d, sufficient vitamin D)
Number of subjects: 118
Study: 34556517

Group type: EXPERIMENTAL
Intervention: Prenotification letter
Number of subjects: 500

Group type: COMPARATOR
Intervention: No prenotification letter
Number of subjects: 500
Study: 34732094

Group type: EXPERIMENTAL
Intervention: Motor Imagery (MI) training for 8 weeks
Number of subjects: 34

Group type: COMPARATOR
Intervention: Physiotherapy training (Control) for 8 weeks
Number of subjects: 34
Study: 33201376

Group type: EXPERIMENTAL
Intervention: Robotic surgery for T1 and borderline ovarian tumors
Number of subjects: 228

Group type: COMPARATOR
Intervention: Robotic surgery for T2 and T3/4 tumors
Number of subjects: 228

Group type: COMPARATOR
Intervention: Current data on robotic surgery
Number of subjects: 228

Group type: COMPARATOR
Intervention: Willingness to participate in clinical studies
Number of subjects: 228
Study: 32459643

Group type: EXPERIMENTAL
Intervention: Blended smoking cessation treatment (n=130)
Number of subjects: 292

Group type: COMPARATOR
Intervention: Face-to-face smoking cessation treatment (n=162)
Number of subjects: 292

Group type: EXPERIMENTAL
Intervention: Face-to-face mode of blended treatment
Number of subjects: 292

Group type: EXPERIMENTAL
Intervention: Web mode of blended treatment
Number of subjects: 292
Study: 34183740

Group type: EXPERIMENTAL
Intervention: Moderate exercise
Number of subjects: 208

Group type: EXPERIMENTAL
Intervention: Vigorous-moderate exercise
Number of subjects: 208

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 208
Study: 35900287

Group type: EXPERIMENTAL
Intervention: Cancer clinical trials (CCTs) participation
Number of subjects: 9
Study: 34798860

Group type: EXPERIMENTAL
Intervention: Vignette-based intervention aiming to reduce stigma and support help-seeking
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Gamified elements and avatar-choice techniques
Number of subjects: 0
Study: 35346351

Group type: EXPERIMENTAL
Intervention: Text Messaging (TM)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Telephone Counseling (TC)
Number of subjects: 0
Study: 34216396

Group type: EXPERIMENTAL
Intervention: MT + Best Medical Management (BMM)
Number of subjects: 107

Group type: COMPARATOR
Intervention: BMM alone
Number of subjects: 107

Group type: EXPERIMENTAL
Intervention: MT + BMM
Number of subjects: 107
Study: 32575660

Group type: EXPERIMENTAL
Intervention: Home-based obesity prevention intervention
Number of subjects: 77
Study: 32603632

Group type: EXPERIMENTAL
Intervention: Internet-delivered cognitive behavioural treatment (ICBT), 8-week treatment
Number of subjects: 59

Group type: COMPARATOR
Intervention: Wait-list control
Number of subjects: 59
Study: 32755610

Group type: EXPERIMENTAL
Intervention: Artificial neural network classifier for promoter identification
Number of subjects: 3

Group type: EXPERIMENTAL
Intervention: Cross-species experiments
Number of subjects: 3
Study: 35862120

Group type: EXPERIMENTAL
Intervention: Financial incentives (process- and outcome-based)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard education and support for hypertension management (Control)
Number of subjects: 0
Study: 33501563

Group type: EXPERIMENTAL
Intervention: Local estrogen group (promestriene 3 × for a week)
Number of subjects: 98

Group type: COMPARATOR
Intervention: Control group (no estrogen)
Number of subjects: 98
Study: 32857610

Group type: EXPERIMENTAL
Intervention: Learn!Grow!Eat!Go! (LGEG)
Number of subjects: 1326

Group type: EXPERIMENTAL
Intervention: Walk Across Texas (WAT!)
Number of subjects: 1326

Group type: COMPARATOR
Intervention: Control (neither Garden nor PA intervention)
Number of subjects: 1326
Study: 35726351

Group type: EXPERIMENTAL
Intervention: Manual chest compression and decompression (MCCD) maneuver
Number of subjects: 105
Study: 32730289

Group type: COMPARATOR
Intervention: Tape-on no tension (0KT)
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Moderate tape tension (ModKT)
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Maximal tape tension (MaxKT)
Number of subjects: 15
Study: 36107429

Group type: EXPERIMENTAL
Intervention: MERM-observed therapy (digital medication event reminder monitor); 15-day TB medication supply dispensed with a MERM device.
Number of subjects: 109

Group type: COMPARATOR
Intervention: Standard directly observed therapy (DOT); in-person therapy.
Number of subjects: 109
Study: 34195988

Group type: EXPERIMENTAL
Intervention: Therapeutic drug monitoring (TDM) arm
Number of subjects: 80

Group type: COMPARATOR
Intervention: Standard of care (control arm)
Number of subjects: 80
Study: 32545056

Group type: EXPERIMENTAL
Intervention: Relaxation therapy intervention
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 60
Study: 36102943

Group type: EXPERIMENTAL
Intervention: High-titer convalescent plasma
Number of subjects: 1239

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 1239
Study: 36227595

Group type: EXPERIMENTAL
Intervention: Warnings with teaspoons of added sugar disclosures
Number of subjects: 5005

Group type: EXPERIMENTAL
Intervention: Warning conditions (groups 6 and 7)
Number of subjects: 5005

Group type: EXPERIMENTAL
Intervention: No claim or imagery condition (group 4)
Number of subjects: 5005

Group type: COMPARATOR
Intervention: Control group (group 1)
Number of subjects: 5005

Group type: EXPERIMENTAL
Intervention: Percentage juice disclosures
Number of subjects: 5005
Study: 34102559

Group type: COMPARATOR
Intervention: Fortified group 0 (FG0) - 0 mg/100 g bLF
Number of subjects: 96

Group type: EXPERIMENTAL
Intervention: Fortified group 1 (FG1) - 38 mg/100 g bLF
Number of subjects: 96

Group type: EXPERIMENTAL
Intervention: Fortified group 2 (FG2) - 76 mg/100 g bLF
Number of subjects: 96
Study: 32212584

Group type: EXPERIMENTAL
Intervention: Toxocara spp. eggs presence
Number of subjects: 103

Group type: EXPERIMENTAL
Intervention: Other zoonotic parasites presence
Number of subjects: 103

Group type: EXPERIMENTAL
Intervention: Taeniid eggs presence
Number of subjects: 103

Group type: EXPERIMENTAL
Intervention: Ancylostoma spp. eggs presence
Number of subjects: 103
Study: 35304932

Group type: EXPERIMENTAL
Intervention: Papaverine (0.12 mg/ml, 1 ml)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Heparin (2 units/ml, 1 ml)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Papaverine (0.12 mg/ml, 1 ml) as rescue treatment
Number of subjects: 100
Study: 33044684

Group type: EXPERIMENTAL
Intervention: ABP 798
Number of subjects: 256

Group type: COMPARATOR
Intervention: Rituximab RP
Number of subjects: 256
Study: 33596883

Group type: EXPERIMENTAL
Intervention: L-Carnitine supplementation (1000 mg)
Number of subjects: 76

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 76
Study: 32468749

Group type: COMPARATOR
Intervention: 1st Generation Antipsychotics
Number of subjects: 350

Group type: EXPERIMENTAL
Intervention: 2nd Generation Antipsychotics
Number of subjects: 350
Study: 35218231

Group type: EXPERIMENTAL
Intervention: Foliglurax 10 mg
Number of subjects: 157

Group type: EXPERIMENTAL
Intervention: Foliglurax 30 mg
Number of subjects: 157

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 157
Study: 32034010

Group type: EXPERIMENTAL
Intervention: IHI Model as a strategy to implement a managed sepsis protocol
Number of subjects: 416
Study: 35738494

Group type: EXPERIMENTAL
Intervention: Macitentan (endothelin-1 receptor antagonist)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 34243806

Group type: EXPERIMENTAL
Intervention: Psychological intervention
Number of subjects: 0
Study: 33377921

Group type: EXPERIMENTAL
Intervention: Nitroglycerin (5 μg/kg in 0.5 ml)
Number of subjects: 113

Group type: COMPARATOR
Intervention: Normal saline (0.5 ml)
Number of subjects: 113
Study: 33342320

Group type: EXPERIMENTAL
Intervention: 10 mg methylphenidate
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (no methylphenidate)
Number of subjects: 0
Study: 32515124

Group type: EXPERIMENTAL
Intervention: Life-behavior-promotion care
Number of subjects: 42

Group type: COMPARATOR
Intervention: Conventional care
Number of subjects: 42
Study: 35139488

Group type: EXPERIMENTAL
Intervention: Eight-section Brocades
Number of subjects: 47

Group type: COMPARATOR
Intervention: Cognitive training
Number of subjects: 47

Group type: EXPERIMENTAL
Intervention: Both groups (Eight-section Brocades and Cognitive training)
Number of subjects: 47
Study: 34048108

Group type: EXPERIMENTAL
Intervention: Clinical hypnosis
Number of subjects: 100

Group type: COMPARATOR
Intervention: Pain education
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Pain catastrophizing measured at the same time as pain
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Pain catastrophizing measured at different times than pain
Number of subjects: 100
Study: 32627599

Group type: EXPERIMENTAL
Intervention: Penicillin G/Hydrocortisone (PenGH)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study: 34881664

Group type: EXPERIMENTAL
Intervention: 2-h class group
Number of subjects: 647

Group type: COMPARATOR
Intervention: 20-min DVD group
Number of subjects: 647

Group type: EXPERIMENTAL
Intervention: Both groups (2-h class and 20-min DVD)
Number of subjects: 647
Study: 34403608

Group type: EXPERIMENTAL
Intervention: Video-based information
Number of subjects: 102

Group type: COMPARATOR
Intervention: Verbally informed
Number of subjects: 102
Study: 35171836

Group type: EXPERIMENTAL
Intervention: Cervical laminoplasty (LP)
Number of subjects: 10834

Group type: EXPERIMENTAL
Intervention: Posterior cervical laminectomy and fusion (LF)
Number of subjects: 10834

Group type: EXPERIMENTAL
Intervention: Anterior cervical discectomy and fusion (mACDF)
Number of subjects: 10834

Group type: EXPERIMENTAL
Intervention: Anterior cervical corpectomy and fusion (ACCF)
Number of subjects: 10834

Group type: EXPERIMENTAL
Intervention: All procedures
Number of subjects: 10834
Study: 35123469

Group type: EXPERIMENTAL
Intervention: Adjusted treatment decision strategy including advice from a treatment algorithm
Number of subjects: 230
Study: 33784968

Group type: EXPERIMENTAL
Intervention: Intravenous iron (ferric derisomaltose (FDI)) 1000 mg
Number of subjects: 54

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: Intravenous iron (ferric derisomaltose (FDI))
Number of subjects: 54
Study: 35293508

Group type: EXPERIMENTAL
Intervention: G1: 1100 μg F/g, pH 4.5 (n = 76)
Number of subjects: 228

Group type: EXPERIMENTAL
Intervention: G2: 750 μg F/g, pH 4.5 (n = 74)
Number of subjects: 228

Group type: EXPERIMENTAL
Intervention: G3: 1100 μg F/g, pH 7.0 (n = 78)
Number of subjects: 228

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 228
Study: 33704351

Group type: EXPERIMENTAL
Intervention: Aflibercept (2 mg/0.05 mL at baseline, 4 weeks, and 8 weeks, as needed from 12 weeks onward)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Panretinal photocoagulation (PRP)
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Aflibercept
Number of subjects: 120
Study: 32337841

Group type: EXPERIMENTAL
Intervention: Clinical plan using a 5-mm expansion of an ITV that encompassed all three GTVs from each of the three ABC-CTs
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: Research plan using a 5-mm expansion of the GTV from only ABC1-CT to create PTV
Number of subjects: 44
Study: 35584738

Group type: EXPERIMENTAL
Intervention: Exergaming (EXE)
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: Balance (BAL)
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: Cycling (CYC)
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: Proprioceptive neuromuscular facilitation (PNF)
Number of subjects: 70

Group type: COMPARATOR
Intervention: Standard care wait-listed control group
Number of subjects: 70
Study: 33206182

Group type: EXPERIMENTAL
Intervention: Laparoscopic sigmoid resection
Number of subjects: 90

Group type: COMPARATOR
Intervention: Conservative treatment
Number of subjects: 90
Study: 35416797

Group type: EXPERIMENTAL
Intervention: CHARISMA counseling intervention
Number of subjects: 407

Group type: COMPARATOR
Intervention: Standard of care counseling support and referrals
Number of subjects: 407